On the stock market since 2026, it operates in the world of health and science. It has 384 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $324.2M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1 year. After that, the company needs to find new money.
The stock trades 58% above the average analyst price target.
On our five-subject report card, EIKN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EIKN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.